Roman Yelensky

Roman Yelensky

Company: Gritstone Oncology

Job title: Executive Vice President & Chief Technology Officer


A 2nd Generation Vaccine to Drive Strong Neutralizing Antibody and CD8 T-cell Responses against SARS-CoV-2 2:30 pm

Mutations in Spike may reduce protection from first generation vaccines Gritstone’s vaccine platform combines two potent vectors to elicit strong antibody and CD8 T cell responses Targets from multiple viral genes are added to maximize CD8 T-cell response breadth and enhance protectionRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.